NK cell therapy abroad
Vietnam, Japan, Thailand, China. The country is not the variable most people think it is — what actually differs is the legal route the treatment travels on, and that is knowable before you book a flight.
Why the search gets typed as a country, and why that is the wrong first question
NK cell therapy — your own natural-killer cells, drawn, expanded in a cleanroom over roughly two weeks, and returned by infusion — is not offered the same way in any two jurisdictions. That is why people search for it as a place: NK cell therapy Vietnam, NK cell therapy Japan, NK cell therapy abroad, where to get NK cell therapy. The instinct behind the search is correct. You genuinely cannot get this everywhere, and where you can, the rules are not the same.
But the country label hides the thing that decides what is actually being sold to you. Everywhere in the world, an NK programme reaches a patient by one of three routes, and the route — not the flag — is what determines the oversight, the paperwork, the honesty of the quote and whether anyone is permitted to say no to you.
| Route | What it means in practice |
|---|---|
| 1. A clinical trial | A published protocol, an ethics committee, fixed entry criteria, and an obligation to report what happened. Often free or subsidised. You are a participant, not a customer, and you may not get the intervention arm. |
| 2. A licensed or notified pathway | A regulator has created a named procedure under which a hospital may treat patients outside a trial. Typically requires a filed indication, a named facility, and in some systems mandatory outcome reporting. You are a patient, and there is a rule with a number on it. |
| 3. Physician discretion | The therapy is neither specifically approved nor specifically prohibited, and the provider operates under general medical-practice licensing. The widest quality range of the three, and the one with the marketing budget. |
Most of what a traveller finds on the open web is route 3, for the plain reason that route 3 is the only one of the three with an incentive to advertise. That does not make every route-3 provider bad. It does mean that if you cannot tell which route you are on, you are not comparing countries at all — you are comparing websites.
The four questions that settle it
What each jurisdiction actually requires, as of 2026
Japan. Provision of regenerative and cell therapy outside a clinical trial is governed by the Act on the Safety of Regenerative Medicine, in force since November 2014. A provider must submit a provision plan, have it reviewed by a certified committee for regenerative medicine, and notify the Ministry of Health, Labour and Welfare before treating anyone. Treatments are sorted into three risk classes with escalating review requirements. The practical effect for a foreign patient is that Japan has a real route 2 for autologous immune-cell work: there is a filing, and there is a regulator on the other end of it. The limit worth understanding is that a notified plan is a safety and procedural clearance. It is not a finding that the treatment works for your condition, and a clinic that presents a notification number as evidence of efficacy is overreading its own paperwork.
Vietnam. New medical techniques are regulated by the Ministry of Health: a technique passes clinical trial and ethical review before it can be approved for clinical use. There is a genuine research history behind autologous immune-cell therapy in Vietnam — a phase I trial of autologous ex-vivo-expanded NK cells and cytotoxic T lymphocytes was published in 2019, and national cell-therapy capacity has been built out steadily since. For a traveller, this means a Vietnamese offer is usually in one of two quite different states: an approved technique at an approved hospital, or a trial you would be enrolling in. Both are legitimate; they are not the same thing, and the consent form is not the same document. Ask which, and ask for the approval or protocol reference.
Thailand. The rule most often quoted in this search is the Medical Council’s restriction on stem-cell treatment, which confines it to haematopoietic bone-marrow transplantation and limits other uses to approved research with scientific and ethical clearance. That description is accurate. It is also the origin of the single most common mistake in this whole topic, which is worth its own section below.
China (Hainan). Since 1 May 2026 the mainland rule is State Council Order No. 818: cell and gene therapy is medicine, for disease, delivered in licensed institutions. Inside the Boao Lecheng International Medical Tourism Pilot Zone a further layer applies under the zone’s 2013 State Council charter: designated tertiary hospitals may deliver clinical-stage cell therapy for filed indications, manufacture the product on-site in their own GMP facilities rather than shipping it in, and report every course into China’s national real-world data programme as a condition of the licence. That is route 2 with a reporting obligation attached — and mandatory reporting is the one feature route 3 structurally cannot have. Order 818 and what the zone licenses →
The trap: a stem-cell rule is not an NK rule
NK cells are not stem cells. They are mature white blood cells of the innate immune system, already differentiated, with no capacity to become other tissue. Stem-cell regulation and immune-cell regulation are frequently written as separate instruments, administered by different bodies, with different requirements.
This matters in both directions, and travellers get caught going each way. Someone reads Thailand’s stem-cell restriction and concludes “NK therapy is banned in Thailand” — a conclusion the rule does not support, because the rule is about a different class of cell. Someone else reads that a jurisdiction is permissive about stem cells and assumes the same latitude applies to an immune-cell product, which is equally unsupported. The same error runs in reverse over China: Order 818 is often summarised online as a ban, when what it actually did was define the lawful route and close the unlicensed one.
What it costs, and why nobody publishes a price
No jurisdiction on this list has a published price list for autologous NK therapy, and the reason is structural rather than coy. An autologous product is manufactured once, for one person, against a course length that a treating panel sets only after reading that person’s records. What a quote is built from is the manufacturing run itself, the number of infusions in the filed course, the day-care admissions each infusion requires, the release testing every batch must pass, and the monitoring afterwards. None of those quantities exist until someone has looked at your case.
So the timing of a quote is diagnostic. A route-3 provider can quote instantly, because nothing has to be decided first. A route-2 programme cannot quote until a panel has decided you are a candidate — and some people are declined, which is the whole reason the quote has to wait. A firm figure offered before anyone has read your pathology is information about the route, not about the price. What a longevity program in China costs, and what is included →
What we can honestly tell you about the others
We run one programme, in one zone, in one country. We can document our own route in detail, and we have — the indications, the course, the exclusions and the limits are all written down on this site, including the parts that are unflattering. What we cannot do is audit an individual clinic in Ho Chi Minh City, Tokyo or Bangkok, and we are not going to pretend otherwise. There is no honest way to rank the world’s NK providers from a desk, and any page that does is selling the ranking.
What does travel across borders is the checklist. Take it to any provider in any country, including this one.
How Hainan answers those questions
For completeness, and so the checklist is not rhetorical: the route here is a licensed pathway under Order 818 and the pilot-zone charter. The cells are autologous. The programme requires a qualifying diagnosis — NK therapy is delivered as post-resection and post-checkpoint-inhibitor maintenance and recurrence prevention across a filed list of solid tumours, plus immune rebuild after chemotherapy or radiation, and it is not offered for longevity, rejuvenation or general wellness. Candidacy is decided by the treating hospital’s oncology panel against filed inclusion criteria, before commercial discussion, and guests are declined. Manufacturing is on-site in the hospital’s own GMP facility with batch release testing, and every course is reported into the national real-world data programme. No hospital in the zone may promise an outcome, and neither will we.
The wellness side of what we do is built on the six-axis retreat and does not involve cells at all. The two are kept apart deliberately, because one of them is medicine.
What is NK cell therapy? Indications, course, exclusions and limits → · Is stem cell therapy safe? → · Why Boao Lecheng →
If you are weighing two or three countries and want a straight answer about whether the panel here would even consider you, write with the outline of your history — diagnosis, staging, what has already been done, and when. A care manager replies within one working day, and the answer is sometimes no. Practical travel questions are covered in planning a trip to Hainan and the 30-day visa-free entry rules.
Frequently asked
Where can I get NK cell therapy abroad?
Autologous NK cell therapy is offered to international patients in several Asian jurisdictions, including Japan, Vietnam, Thailand and China. The country matters less than the legal route the therapy travels on in that country: a clinical trial, a licensed or notified treatment pathway, or physician discretion under general medical-practice licensing. Those three routes produce very different products, and which one you are being offered is knowable before you book a flight.
Is NK cell therapy available in Vietnam?
Vietnam regulates new medical techniques through its Ministry of Health: a technique passes clinical trial and ethical review before it may be approved for clinical use. Autologous immune-cell therapy has a genuine research history there, including a published phase I trial of autologous ex-vivo-expanded NK cells and cytotoxic T lymphocytes in 2019. For a traveller the practical question is which state a given programme is in — an approved technique at an approved hospital, or a trial you would be enrolling in — and the provider should be able to name it.
Is NK cell therapy legal in Japan?
Japan has regulated provision of regenerative and cell therapy outside clinical trials under the Act on the Safety of Regenerative Medicine, in force since November 2014. Providers must submit a provision plan, have it reviewed by a certified committee for regenerative medicine, and notify the Ministry of Health, Labour and Welfare before treating patients. Treatments are sorted into three risk classes with escalating review. A notified plan is a safety and procedural clearance, not a finding that the treatment works for a particular condition.
Is NK cell therapy available in Thailand?
Thailand's most-quoted rule is the Medical Council's restriction on stem-cell treatment, which confines it to haematopoietic bone-marrow transplantation with other uses limited to approved research. That rule is written about stem cells. NK cells are mature immune cells, not stem cells, so the stem-cell restriction may not be the regulation governing an NK product at all. Ask a Thai provider which regulation they treat under by name, rather than inferring it from the stem-cell rule.
How much does NK cell therapy cost abroad?
No jurisdiction publishes a price list for autologous NK therapy, because the product is manufactured once, for one patient, to a course length a treating panel sets after reading that patient's records. Cost is driven by the manufacturing run, the number of infusions in the filed course, day-care admissions, release testing and monitoring. A provider who can quote a firm figure before anyone has read your pathology is telling you something about their legal route, not about the price.
Which country is best for NK cell therapy?
There is no best country in the abstract, and any page that ranks the world's providers is selling something. What differs between programmes is answerable in four questions: which legal route is this, are the cells autologous or donor-derived, does the programme require a qualifying diagnosis, and who decides candidacy and can they decline you. A programme that requires an indication and can say no is a programme a regulator has bounded.
Write to us →Tell us where you’re starting from — a care manager replies within one working day.Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.